All participants will receive vedolizumab IV infusion on Weeks 0, 2, 6, 14 and 22 along with adalimumab 160 mg, SC injection at Week 0, 80 mg at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with methotrexate tablets orally, once weekly from Weeks 0 up to Week 34. In monotherapy phase, all participants will receive vedolizumab IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.